Head-to-head evidence
Interferon beta-1b vs peginterferon beta-1a
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Sclerosis
Shared mechanisms: Interferon beta receptor (type I IFN signaling) · Type I interferon receptor · full Multiple Sclerosis pipeline
Interferon beta-1b
Marketed by Bayer
NCT00099502 · Phase 3 · completed
The study was a large randomized, triple-blind, active-controlled trial comparing two interferon beta-1b doses with Copaxone, with relapse hazard as the clinical primary endpoint. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
peginterferon beta-1a · Plegridy
Marketed by Biogen
NCT00906399 · Phase 3 · completed
This was a large, randomized, triple-blind, placebo-controlled trial with 1,516 participants. Its primary clinical endpoint, annualized relapse rate at one year, was statistically significantly lower with both peginterferon beta-1a schedules than with placebo (p=0.0007 for every 2 weeks and p=0.0114 for every 4 weeks).
Next expected readout: May 2027 · NCT03958877 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Interferon beta-1b's landscape · peginterferon beta-1a's landscape